A Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeated Subcutaneous (SC) Doses of REMD-477 in Subjects With Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs REMD 477 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors REMD Biotherapeutics
- 25 Sep 2017 Planned End Date changed from 1 Nov 2017 to 1 Feb 2018.
- 25 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
- 25 Sep 2017 Status changed from recruiting to active, no longer recruiting.